within Pharmacolibrary.Drugs.ATC.N;

model N02AE01_1
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.00085,
    adminDuration  = 600,
    adminMass      = 0.3 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.188,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.43,
    k12             = 37,
    k21             = 37
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N02AE01_1</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Buprenorphine is a semi-synthetic opioid used primarily for pain management and opioid dependence therapy. It acts as a partial agonist at mu-opioid receptors, providing analgesia and mitigating opioid withdrawal symptoms.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics after intravenous administration in healthy adults.</p><h4>References</h4><ol><li><p>Hakomäki, H, et al., &amp; Kokki, M (2021). Pharmacokinetics of buprenorphine in pregnant sheep after intravenous injection. <i>Pharmacology research &amp; perspectives</i> 9(2) e00726–None. DOI:<a href=\"https://doi.org/10.1002/prp2.726\">10.1002/prp2.726</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33619904/\">https://pubmed.ncbi.nlm.nih.gov/33619904</a></p></li><li><p>Enomoto, H, et al., &amp; Messenger, KM (2022). Pharmacokinetics of intravenous, oral transmucosal, and intranasal buprenorphine in healthy male dogs. <i>Journal of veterinary pharmacology and therapeutics</i> 45(4) 358–365. DOI:<a href=\"https://doi.org/10.1111/jvp.13056\">10.1111/jvp.13056</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35445748/\">https://pubmed.ncbi.nlm.nih.gov/35445748</a></p></li><li><p>Steagall, PV, et al., &amp; Beaudry, F (2020). Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. <i>BMC veterinary research</i> 16(1) 154–None. DOI:<a href=\"https://doi.org/10.1186/s12917-020-02364-w\">10.1186/s12917-020-02364-w</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32448336/\">https://pubmed.ncbi.nlm.nih.gov/32448336</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N02AE01_1;
